Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 22,009 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Atlanta, Georgia • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more

Conditions: Lung Cancer, NSCLC, Brain Metastases
Interventions: Alectinib, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Joshua Palmer; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Columbus, Ohio

Conditions: Late Life Depression (LLD), Depression - Major Depressive Disorder
Interventions: High-intensity (6 mA) transcranial direct current stimulation (tDCS); Device
Lead sponsor: Andre Russowsky Brunoni; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes, Sleep, Stress
Interventions: Mindfunlness Meditation; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Facet Joints; Degeneration, Back Pain, Facet Joint Pain
Interventions: Alocyte low dose, Alocyte medium dose, Alocyte high dose; Drug
Lead sponsor: Alimorad Farshchian; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
Interventions: Diagnostic Mammography, Resection, Ultrasound Imaging, Twinkling Marker Placement; Procedure · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Durvalumab 50 MG/ML; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: Chicago, Illinois • Scarborough, Maine • Boston, Massachusetts + 2 more

Conditions: Prosthesis User, Amputation, Upper Limb Amputation at the Wrist, Upper Limb Amputation Above Elbow (Injury), Upper Limb Amputation Below Elbow (Injury)
Interventions: Qualitative Analysis; Other
Lead sponsor: Louis Stokes VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 178 participants
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions: Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 698
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more

Conditions: Advanced or Metastatic Solid Tumors
Interventions: HM16390, pembrolizumab; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan

Conditions: Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions: Synthroid, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: ADHD
Interventions: VR Treatment, VR Active Control; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 8 Years to 12 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Skin Diseases, Photoaging, Skin Hydration
Interventions: BT-Analyze bioimpedance skin hydration measurement; Other
Lead sponsor: IAS Skin Care; Industry
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Rectal Adenocarcinoma, Rectal Cancer
Interventions: High Rare Dose Rectal Brachytherapy Boost; Radiation
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Aurora, Colorado • Rochester, New York • Portland, Oregon

Conditions: Breast Cancer, Kidney Neoplasms, Liver Neoplasms
Interventions: contrast agent perflutren lipid, Ultrasound Imaging; Drug · Device
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Athletic Performance, Neuromuscular Adaptations, Lower Limb, Chiropractic Manipulation
Interventions: Manual Therapy Procedure: Chiropractic Ankle Manipulation; Other
Lead sponsor: Northeast College of Health Sciences; Other
Eligibility: 18 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seneca Falls, New York

Conditions: Smoking, Smoking Cessation, Second Hand Tobacco Smoke
Interventions: Refer2Quit; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL Variant
Interventions: Venetoclax, Acalabrutinib; Drug
Lead sponsor: Zulfa Omer; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type2diabetes, Diabetic Kidney Disease
Interventions: Investigational Product - MIB 626, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Neoplasm
Interventions: Ifinatamab Deruxtecan; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • St. Petersburg, Florida + 12 more

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Interventions: Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib, Tremelimumab; Drug · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Metastases
Interventions: Yttrium-90 (Y-90) resin microspheres; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcohol Use Disorder
Interventions: CI-581a, CI-581b, MBRP, MET; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: T2D, Blood Pressure, Cardiometabolic Health
Interventions: Controlled diet: Potato-rich healthy dietary pattern, Controlled diet: Typical Western-style dietary pattern; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Blacksburg, Virginia

Search by objective public record fields.

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

tDCS for Late-Life Depression

My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes

Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Evaluating the Experience of Upper Limb Prosthesis Use

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

Virtual Reality Attention Management

Driving Time and Facial Skin Hydration Asymmetry in Florida Drivers

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

Squat Jump Performance and Chiropractic Ankle Manipulation

Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

NAD Augmentation in Diabetes Kidney Disease

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking

Potatoes, Type 2 Diabetes, and Cardiometabolic Health